Flash Sell! Take Gains on This Pharma Play
Clinical trials are generally set up with guidance and input from the FDA, in order to have something that the regulator finds acceptable as the basis for a drug approval. One biotech is deviating from that protocol, and is sending shares swooning…
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Ray Blanco’s FDA Trader
Ray Blanco’s FDA Trader focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.